This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Succeeding in the Management of Heart Failure: The Evolving Role of the Family Practitioner

Succeeding in the Management of Heart Failure: The Evolving Role of the Family Practitioner



Time to Complete

1 hour


May 14, 2019


May 14, 2020
Add to Queue

Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider

Provided by Integrity Continuing Education, Inc.

Commercial Supporter

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Program Description

Heart Failure (HF) continues to increase in both prevalence and incidence, and as the population continues to age, it is expected that the prevalence of this disease will continue to rise. Most patients with HF will present in a family practice setting; therefore, the community management of HF has become increasingly important, and the role of family practice providers even more crucial. Improving the reliability of diagnosis in primary care is essential to improving symptoms, quality of life, and disease prognosis. Furthermore, an early and correct diagnosis is needed when there may be no symptoms since treatment can delay or reverse disease progression.

Primary care physicians are in a pivotal position to make decisions regarding appropriate further investigation, treatment and referral, and to continue to provide education and support to patients during the post-discharge period. This activity will provide family practice providers with practical strategies to more effectively diagnose and manage patients with HF, as well as to employ motivational interviewing techniques and shared decision-making to ensure patients are informed regarding their condition and fully able to contribute to decision-making about future treatment options.

Intended Audience

This educational initiative has been designed for family physicians involved in the prevention, diagnosis, and post-discharge management of patients with HF.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe primary care clinicians’ role in the monitoring, follow-up, and post-hospital discharge management of patients with HF
  • Identify key components for the diagnosis of HF
  • Individualize HF treatment based on patients’ clinical presentation and in alignment with the latest evidence-based guideline recommendations for management
  • Employ motivational interviewing to encourage patients to take an active role in disease management

Conflict Of Interest Disclosure Policy

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

The faculty/planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity.


Keith C. Ferdinand, MD
Professor of Medicine
Department of Cardiology
Tulane University School of Medicine
Gerald S. Berenson Endowed Chair in Preventative Cardiology
New Orleans, Louisiana

Dr. Ferdinand discloses the following:
Consulting Fees: Boehringer Ingelheim, Inc., Lilly USA, Novartis Pharmaceuticals Corporation, Galderma Laboratories, L.P., Quantum Genomics, Janssen Scientific Affairs, LLC.

Javed Butler, MD, MPH, MBA
Professor and Chair of Medicine
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Dr. Butler discloses the following:
Consulting Fees: Amgen, Array BioPharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Inc., Boehringer Ingelheim, Inc., Bristol-Myers Squibb, CVRx, G3 Pharmacuticals, Innolife Co., LTD., Janssen Scientific Affairs, LLC., Luitpold Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Relypsa, Inc., Stealth Peptides, Inc., scPharmaceuticals, Vifor Pharma, ZS Pharma, Inc.

Accredited Provider Disclosure

Rachel Brown, PharmD, MPH, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education and Novartis Pharmaceuticals Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


There are no fees for participating and receiving CME credit for this activity. During the period of May 14, 2019 through May 14, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A certificate will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher. Please proceed with the activity until you have successfully passed the post-test, completed the evaluation and received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or

If you have any questions relating to your certificate or other issues with this activity, please contact

Privacy Policy


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue